X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the advancement of company's CLD-101 designed to protect and better distribute the anti-cancer virus to sites of tumors distant from the main tumor mass.
Lead Product(s): CLD-101
Therapeutic Area: Oncology Product Name: CLD-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ladenburg Thalmann
Deal Size: $6.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 19, 2024
Details:
CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.
Lead Product(s): NSC.CRAd-S-pk7
Therapeutic Area: Oncology Product Name: CLD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: City of Hope
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
The financing will enable Calidi to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.
Lead Product(s): NSC-CRAd-S-pk7
Therapeutic Area: Oncology Product Name: CLD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jackson Investment Group
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 23, 2023
Details:
SNV1 is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC Based Oncolytic Virus) loaded with the oncolytic vaccinia virus Cal1, targeting a variety of solid tumors including metastatic melanoma, triple negative breast cancer, and advanced HNSCC.
Lead Product(s): AD-MSC-based Oncolytic Virus
Therapeutic Area: Oncology Product Name: SNV1
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CIRM
Deal Size: $3.1 million Upfront Cash: Undisclosed
Deal Type: Funding December 14, 2022
Details:
SNV1 (AD-MSC based oncolytic virus) is an AD-MSC-delivering CAL1 oncolytic virus used for the treatment of solid tumors (metastatic breast, melanoma, head and neck).
Lead Product(s): AD-MSC Based Oncolytic Virus
Therapeutic Area: Oncology Product Name: SNV1
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
The SNV platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent, such as the vaccinia virus SNV1, and is anticipated to be used in combination with various immunotherapy agents, including blocking antibodies.
Lead Product(s): AD-MSC Based Oncolytic Virus
Therapeutic Area: Oncology Product Name: SNV1
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
The agreement grants to Calidi commercial exclusivity in using neural stem cells with the adenovirus known as CRAd-pk-S-7 for oncolytic virotherapy.
Lead Product(s): CRAd-pk-S-7,Allogeneic Neural Stem Cell
Therapeutic Area: Oncology Product Name: CRAd-pk-S-7
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: City of Hope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 16, 2021
Details:
Northwestern granted to Calidi a worldwide, 12 year exclusivity for use of the clinical data in the commercial development of NSC-CRAd-S-pk7 for therapeutic and preventive uses in oncology and a right of NU IND 17365 which relates to treatment of newly diagnosed glioma.
Lead Product(s): NNV1
Therapeutic Area: Oncology Product Name: NSC-CRAd-S-pk7
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Calidi Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2021
Details:
U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM).
Lead Product(s): CERC-006
Therapeutic Area: Rare Diseases and Disorders Product Name: CERC-006
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Cerecor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Calidi’s presentations will highlight findings from translational research on the potential use of the CAL1 vaccinia virus, as well as insights from clinical trials analyzing the potential use of Calidi’s autologous SVF delivery platform.
Lead Product(s): CAL1 vaccinia virus
Therapeutic Area: Oncology Product Name: SVF-CAL1
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
